Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 | Zendy

Michael B. Atkins | Zendy; Sandra J. Lee | Zendy; Bartosz Chmielowski | Zendy; Ahmad A. Tarhini | Zendy; Gary I. Cohen | Zendy; ThachGiao Truong | Zendy; Helen Moon | Zendy; Diwakar Davar | Zendy; Mark Allen O’Rourke | Zendy; Joseph J. Stephenson | Zendy; Brendan D. Curti | Zendy; Walter J. Urba | Zendy; Joanna M. Brell | Zendy; Pauline Funchain | Zendy; Kari Kendra | Zendy; Alexandra P. Ikeguchi | Zendy; Anthony J. Jaslowski | Zendy; Charles Bane | Zendy; Mark Taylor | Zendy; Madhuri Bajaj | Zendy; Robert M. Conry | Zendy; Robert J. Ellis | Zendy; Theodore F. Logan | Zendy; Noel Laudi | Zendy; Jeffrey A. Sosman | Zendy; David G. Crockett | Zendy; Andrew L. Pecora | Zendy; Ian J. Okazaki | Zendy; Sowjanya Reganti | Zendy; Sunandana Chandra | Zendy; Samantha Guild | Zendy; Helen X. Chen | Zendy; Howard Streicher | Zendy; Jedd D. Wolchok | Zendy; Antoni Ribas | Zendy; John M. Kirkwood | Zendy

Open Access

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Author(s) -

Michael B. Atkins,

Sandra J. Lee,

Bartosz Chmielowski,

Ahmad A. Tarhini,

Gary I. Cohen,

ThachGiao Truong,

Helen Moon,

Diwakar Davar,

Mark Allen O’Rourke,

Joseph J. Stephenson,

Brendan D. Curti,

Walter J. Urba,

Joanna M. Brell,

Pauline Funchain,

Kari Kendra,

Alexandra P. Ikeguchi,

Anthony J. Jaslowski,

Charles Bane,

Mark Taylor,

Madhuri Bajaj,

Robert M. Conry,

Robert J. Ellis,

Theodore F. Logan,

Noel Laudi,

Jeffrey A. Sosman,

David G. Crockett,

Andrew L. Pecora,

Ian J. Okazaki,

Sowjanya Reganti,

Sunandana Chandra,

Samantha Guild,

Helen X. Chen,

Howard Streicher,

Jedd D. Wolchok,

Antoni Ribas,

John M. Kirkwood

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.22.01763

Subject(s) - trametinib , medicine , ipilimumab , dabrafenib , nivolumab , clinical endpoint , melanoma , progression free survival , oncology , population , discontinuation , surgery , clinical trial , vemurafenib , immunotherapy , cancer , chemotherapy , metastatic melanoma , cancer research , mapk/erk pathway , environmental health , kinase , biology , microbiology and biotechnology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research